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RAC3 is a coactivator of glucocorticoid receptor and nuclear factor-jB (NF-jB) that is usually over-
expressed in tumors and which also has important functions in the immune system. We investi-
gated the role of the inﬂammatory response in the control of RAC3 expression levels in vivo and
in vitro. We found that inﬂammation regulates RAC3 levels. In mice, sub-lethal doses of lipopolysac-
charide induce the increase of RAC3 in spleen and the administration of the synthetic anti-inﬂam-
matory glucocorticoid dexamethasone has a similar effect. However, the simultaneous treatment
with both stimuli is mutually antagonistic. In vitro stimulation of the HEK293 cell line with tumor
necrosis factor (TNF), one of the cytokines induced by lipopolysaccharide, also increases the levels of
RAC3 mRNA and protein, which correlates with an enhanced transcription dependent on the RAC3
gene promoter. We found that binding of the transcription factor NF-jB to the RAC3 gene promoter
could be responsible for these effects. Our results suggest that increase of RAC3 during the inﬂam-
matory response could be a molecular mechanism involved in the control of sensitivity to both pro-
and anti-inﬂammatory stimuli in order to maintain the normal healthy course of the immune
response.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
RAC3 (also known as SRC-3, AIB1, ACTR, p/CIP, TRAM-1) is a
member of the p160 nuclear receptor coactivator family. The gene
for this molecule was reported to be ampliﬁed in 5–10% of human
breast tumors and the protein overexpressed in 60% of tumors,
suggesting that RAC3 provides a growth advantage for breast
cancer cells [1]. RAC3 is a bona ﬁde oncogene and plays a role ininitiation and progression of mammary gland tumorigenesis
[34,40].
RAC3 was ﬁrstly identiﬁed as a coactivator for nuclear receptors
[1,20,33], but it was later described as a coactivator for transcription
factors which are structurally not related to the original targets.
Such is the case of NF-jB [38] whose role in oncogenesis in addition
to the immune response and several physiological functions have
been described in detail [2,15,19]. Therefore, the investigation of
the RAC3 role in tumors not dependent of steroid hormones, as well
as additional functions not strictly related to nuclear receptors, is
not surprising. In fact, most clinical studies have revealed the
aberration of RAC3 in a broad spectrum of malignancies with high
frequency, including pancreatic adenocarcinoma, hepatocellular
carcinoma, gastric cancers, esophageal squamous cell carcinoma,
and prostate cancer [14,16,18,31,37,40,42]. Moreover, there is
strong evidence that some functions of RAC3 could be occurring
through cytoplasmatic actions [8,27].
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dependent of their expression levels and in a few cases, the gene
ampliﬁcation is the cause of its increase. Therefore, the molecular
mechanisms that control the RAC3 levels deserve to be investi-
gated. In that sense it was previously described that RAC3 gene
is a target of E2F, being an E2F coactivator that promotes the cell
cycle progression [26]. In addition, a posttranslational mechanism
that controls its turnover was also described [22].
Although its oncogenic role appears to be more relevant, this
nuclear receptor coactivator plays additional important functions
in the control of growth and development involving cell prolifera-
tion, migration, differentiation, somatic growth, sexual maturation,
female reproductive function, and vaso-protection [11,21,25,39].
More recently it was also described as an important mediator of
the inﬂammatory response and septic shock [23,24].
The cytokines IL-1, IL-6 andTNFare theprincipalmediatorsof the
inﬂammatory response but their over-induction and sustained bio-
logical activities are responsible for several undesirable effects, like
septic shock and chronic disorders [4,9]. However, these inﬂamma-
tory cytokines activate the hypothalamic–pituitary–adrenal axis
(HPA) inducing the elevation of the systemic glucocorticoid levels
[4,32]. These hormones are the most important anti-inﬂammatory
and immunosuppressive agents that contain the overreaction of
the immune system as well as autoimmune reactions through inhi-
bitionof cytokinegeneexpressionand their biological actions [3,17].
RAC3 is a coactivator for the CG receptor (GR) and NF-jB. There-
fore, in this work, we investigated if the inﬂammatory response
may regulate the expression levels of RAC3 in vivo and in vitro.
2. Materials and methods
2.1. Cell culture and reagents
The human embryonic kidney HEK293 cells were cultured in
DMEM (Gibco Laboratories, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum (FBS) (Invitrogen), penicillin (100 U/
ml) and streptomycin (100 mg/ml). Cells were maintained at 37 C
in a humidiﬁed atmosphere with 5% CO2. Unless stated otherwise,
all reagents were obtained from Sigma Chemical Co., Invitrogen,
Promega or Santa Cruz Biotechnology, USA. For all the experiments,
the relative densitometric units (RDU) were determined from the
original gel or picture using the NIH-Image J software.
2.2. In vivo model
All animal experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health. Male BALB/c mice, 6–8 weeks,
weighing approximately 25–30 g, were purchased at the Buenos
Aires University (Argentine). All mice were maintained in our ani-
mal facility with food and water at libitum for a minimum of
7 days before experimentation.
Mice were randomly divided into four groups: control group,
LPS group (Escherichia coli 0111:B4-Sigma, 2 mg/kg, sublethal
dose), dexamethasone (Dex, 6 mg/kg) and Dex plus LPS group.
The group of Dex plus LPS was pre-treated with Dex 1 h prior intra-
peritoneal (i.p.) administration of LPS. The control group was trea-
ted i.p. with 200 ll of PBS. Animals were euthanized 6 or 24 h after
LPS administration. The spleen was surgically removed and total
RNA was extracted using TRIzol reagent (Invitrogen) following
the manufacturer’s instructions.
2.3. Expression vectors and reporter plasmids
The reporter plasmid containing a fragment of 2312 bp of the 50
regulatory sequence of the RAC3 gene (1970 to +335) upstreamof Luciferase gene (PromRAC3-Luc), was previously described
[13]. The RelA (pRc-RelA) and ssIjB (pRc-IjBss, carrying the
mutated IjB at Ser32 and Ser36 to prevent phosphorylation and
proteolysis) expression vectors were previously described [28].
The RAC3 siRNA (speciﬁc for RAC3 without effect over the others
p160 family members), GRE-Luc and jB-Luc plasmids were previ-
ously described [13,38].
2.4. Luciferase assays
HEK293 cells were plated in 24-well plates 24 h prior to trans-
fection at a density of 100,000 cells/well. Cells were transiently
transfected with a total of 0.2 lg of DNA (including pRc-RelA
and/or pRc-IjBss plus 20 ng of promRAC3-Luc or GRE-Luc or
jB-Luc plasmids and 5 ng RSV-b Gal) using the calcium phosphate
precipitation method as previously described [29]. The medium
was replaced after 5 h and cells were stimulated with 500 nM of
Dex and/or 10 ng/ml of human TNF 16 h later.
The assays for luciferase and b-Galactosidase activity were per-
formed after 24 h of treatment using the appropriate substrates
following the manufacturer’s protocols (Promega Corp.). To
achieve transfections with a constant amount of DNA, appropriate
amounts of the parental empty expression vector were added to
each well. In some experiments, cells were pre-incubated with
NF-jB inhibitor Sulfasalazine (Sz) for 30 min before stimulation
with TNF.
2.5. Real time PCR
Assays were performed as previously described [13]. Brieﬂy,
total RNA was isolated from HEK293 cells or spleen tissue by using
the TRIzol protocol (Invitrogen). Reverse transcription was carried
out by using the SuperScript II kit (Invitrogen) following the man-
ufacturer’s instructions. For gene expression analysis, qPCR was
performed by using sequence-speciﬁc primers for: hRAC3 forward
50-AAGTGAAGAGGGATCTGGA-30 and reverse 50- CAGATGACTACCA
TTTGAGG-30, and hGADPH forward 50-TCTCCTCTGACTTCAACAGC-
30 and reverse 50-GTTGTCATACCAGGAAATGA-30 was used as an
internal control.
To determine the effectiveness of the inﬂammatory response to
LPS, spleen tissue IL-6, IL-1b and TNFmRNA levels were determined
by qPCR [30]. It was performed using primers for: mIL-6 forward 50-
CCACTTCACAAGTCGGAGGCTTA-30 and reverse 50-GCAAGTGCATC
ATCGTTGTTCATAC-30, mIL-1 b forward 50-CAACTGTGAAATGCCA
CC-30 and reverse 50-GTGATACTGCCTGCCTGA-30, mTNF-a forward
50-AAGCCTGTAGCCCACGTCGTA-30 and reverse50-GGCACCACTAGTT
GGTTGTCTTTG-30, and mRAC3 forward 50-ACATGGTGCATATGAA-
CAGC-30 and reverse 50-GATGTCAGCAGTATTTCTGATCG-30. Speciﬁc
mRNA expression levels were normalized to the housekeeping gene
b-actin forward 50-GCCAACCGTGAAAAGATGAC-30 and reverse 50-
ACATGGCTGGGGTGTTGAA-30, and the results are expressed as the
fold change compared to control.
2.6. Western blot analysis
Western blot were performed as previously described [28].
Brieﬂy, for RAC3 and RelA expression analysis, proteins were sep-
arated in an 8% SDS–PAGE. Protein samples were blotted to a PVDF
membrane. After incubation with the corresponding primary and
secondary antibodies, blots were developed by enhanced chemilu-
minescence (New England Nuclear, Boston, MA, USA).
2.7. Chromatin immunoprecipitation (ChIP)
After incubation for 45 min with 10 ng/ml of TNF, HEK293 cells
were ﬁxed with 1% of formaldehyde for 10 min and the ChIP was
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were pre-incubated with the NF-jB inhibitor Sulfasalazine (SZ) for
30 min before stimulation with TNF.
Immunoprecipitation was performed using 25 lg of DNA in
RIPA buffer with anti-Rel-A for 18 h at 4 C in an orbital rocker.
Immunoprecipitates were then incubated with Gamma Bind
Sepharose-G protein (GE) for 2 h at 4 C in an orbital rocker. After
three washes, DNA was eluted from the pellets and proteins were
digested with Proteinase K. Samples were heated with shaking at
65 C for 4 h to reverse crosslinking. The extract containing DNA
was precipitated with ethanol 70% and sodium acetate 0.3 M. Sam-
ples were resuspended in buffer TE and relative template enrich-
ment after immunoprecipitation with respect to the input was
determined by real time PCR using the primers 50-TCCACAAATGT-
TAGGTATTACTGG-30 and 50-GGGAGCTCCCTCGGGATCCG-30 that
correspond to 199 jB elements of the RAC3 gene promoter. The
speciﬁc signal was calculated as the difference between the mean
value obtained from speciﬁc antibodies data and subsequently nor-
malized to input values. Results were expressed as fold of increase
relative to the input value.
3. Results
3.1. Inﬂammatory response up-regulates the RAC3 levels in the spleen
In order to analyze the effects of the inﬂammatory response and
GC over the expression levels of RAC3, mice were treated with a
sub-lethal dose of 2 mg/kg of LPS or 6 mg/kg of the synthetic glu-
cocorticoid dexamethasone (Dex) or both simultaneously and the
RAC3 mRNA expression was determined by qPCR in the spleen
after 24 h.
As shown in Fig. 1A, this dose of LPS effectively induces an
inﬂammatory response as determined by the expression of the
inﬂammatory cytokines IL-1, IL-6 and TNF in the spleen. However,
this response was signiﬁcantly inhibited when Dex was adminis-
tered 1 h before to LPS.
Fig. 1B shows that spleen from mice stimulated with LPS for
24 h have increased levels of mRNA for RAC3 as compared with
the controls. Moreover, although GC plays an anti-inﬂammatory
role, inhibiting the expression and activity of the inﬂammatory
cytokines [3,17], Dex is a very good inducer of the RAC3 gene
expression. However, the simultaneous treatment with both stim-
uli does not induce a synergic enhancement of RAC3 levels, but
also, it results in a mutual antagonism, inhibiting the coactivator
gene expression to basal levels.
3.2. TNF induces the increase of RAC3 gene expression
TNF is an inﬂammatory cytokine induced early in the inﬂamma-
tory response that has multiple biological activities including its
role in tumor development and metastasis [12,28,36].
Therefore, we investigated if TNF and Dex are capable of induc-
ing the increase of RAC3 gene expression. For these experiments,
we used the HEK293 cell line, which has receptors for TNF and
GC. Similar to that observed in vivo, each one of these stimuli
increases the expression levels of RAC3 mRNA (Fig. 2A) and protein
(Fig. 2B), as determined by qPCR and western blot at 24 h after
addition of TNF or Dex. However, the simultaneous treatment with
both stimuli does not produce a mutual antagonism as observed
between LPS and Dex.
In order to determine if TNF and Dex have a direct effect over
the RAC3 gene promoter, HEK293 cells were transfected with a
reporter plasmid containing luciferase under the control of a frag-
ment of the RAC3 promoter (from 1970 to +335, containing puta-
tive target sequences for NF-jB binding) and stimulated with TNF,
Dex or both together.Fig. 2C shows that TNF or Dex increases the transcription
dependent on the RAC3 promoter and, again, the simultaneous
treatment with both stimuli does not produce a mutual antago-
nism, showing instead luciferase levels higher than when each
one of these stimuli was applied separately.
3.3. NF-jB increases the transcription of RAC3 gene and could be a
signal by which inﬂammatory cytokines upregulate the coactivator
levels
The transcription factor NF-jB could be activated by multiple
signals, being TNF one of them [15].
In order to determine if the effect of TNF over the RAC3 expres-
sion could be, at least partially mediated by NF-jB activation, we
performed experiments using a speciﬁc inhibitor. We analyzed
the levels of RAC3 mRNA or RAC3 gene promoter activity in
HEK293 cells stimulated with TNF in the presence or not of Sulfa-
salazine (SZ), a potent and speciﬁc inhibitor of NF-jB activation
[28,35].
Fig. 2A–C shows that SZ clearly inhibits the increase of RAC3
induced by TNF. Therefore, in order to conﬁrm that NF-jB could
be directly involved in the increase of both the RAC3promoter activ-
ity and mRNA expression levels, we analyzed if this transcription
factor is able to bind the putative NF-jB target sequence present
in the RAC3 promoter fragment that we used in the reporter assays.
Therefore, we performed ChIP experiments, where the Rel-A (the
active subunit of themost abundantNF-jB dimer)was immunopre-
cipitated after TNF stimulus and the DNA bound to these complexes
was ampliﬁed by qPCRusing speciﬁc primers. Fig. 2D shows a signif-
icant increase on the NF-jB binding to this sequence in response to
TNF, which was blocked by the addition of SZ.
In order to conﬁrm the functional role of NF-jB on the RAC3
gene promoter, we performed additional experiments analyzing
the effects of Rel-A. HEK293 cells were transfected with an expres-
sion vector for Rel-A, or the control empty vector and simulta-
neously, with or without the expression vector for the super-
repressor IjB (ssIjB). This protein is unable to be phosphorylated
and degraded, keeping NF-jB inactive. We analyzed the effect of
Rel-A and/or ssIjB overexpression over RAC3 gene promoter activ-
ity, levels of RAC3 mRNA and proteins. Fig. 3 shows these results:
the increase of Rel-A induces an enhanced transcriptional activity
of the RAC3 gene promoter (Fig. 3A) giving increased levels of
RAC3 mRNA (Fig. 3B) and RAC3 protein (Fig. 3C). The ssIjB overex-
pression signiﬁcantly inhibited all these effects.
3.4. NF-jB and GR-mediated transactivation require RAC3 expression
In physiological conditions, most of the immune response
involves the expression ofNF-jB target geneswhile the anti-inﬂam-
matory effects require GR. In order to induce the expression of their
target genes,GRandNF-jBuses several coactivators, likeRAC3, SRC-
1 and TIF-2, all members of the p160 family. However, is not clear
whether there is a speciﬁc requirement for RAC3 for GR and NF-jB
activity, or if othermembers could compensate for some RAC3 func-
tions. Therefore,we investigated the impact of RAC3depletion in the
activity of GR, NF-jB and their mutual antagonism [38].
A low or undetectable expression pattern of p160 coactivators is
usually found in normal tissues. On the other hand, HEK293 are
non-tumoral cells that also express almost undetectable levels of
these molecules [8]. Thus, this cell line is a good model to investi-
gate the effect of RAC3 depletion on NF-jB and GR-dependent
transcription, without the possible compensatory effect due to
overexpression of the other p160 coactivators.
Therefore, cells were transfected with a RAC3 siRNA expression
vector or the scrambled control. The NF-jB and GR transcriptional
activity were analyzed by reporter assays using the jB-Luc or
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Fig. 1. Pro- and anti-inﬂammatory signals regulate the RAC3 expression: Balb/c mice were treated (ip) with LPS (2 mg/kg), Dex (6 mg/kg) or Dex plus LPS and sacriﬁced after
6 (A) or 24 h (B) of treatment. The mRNA levels of pro-inﬂammatory cytokines TNF, IL-6 and IL-1b (A) or RAC3 (B) from spleen were determined by qPCR, using speciﬁc
primers. Diagram bars correspond to the average ± SD of ﬁve animals, normalized to Actin and expressed as a ratio respect to the control condition. Results were analyzed by
Tukey’s Test.
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TNF (10 ng/ml), Dex (500 nM) or both simultaneously.
As shown in Fig. 4, under normal RAC3 gene expression and as
expected, TNF induced the NF-jB -mediated transcription, which
was inhibited by Dex (Fig. 4A) while Dex induced the GR-mediated
transcription, that was inhibited by TNF (Fig. 4B) [38]. However, all
NF-jB- and GR-dependent transcription was signiﬁcantly inhibited
when RAC3 expression was blocked (Fig. 4C, at ampliﬁed scale).
Moreover, the mutual antagonism between both signals was not
detected in the absence of RAC3 expression.
These results demonstrate that RAC3 is required for the
NF-jB- and GR-mediated transcription, as well as for their mutual
antagonism. Moreover, in non-tumoral cells, which have limiting
quantities of p160 coactivators [8], RAC3 cannot be replaced by
the other members. Therefore, their up regulation by inﬂammatory
cytokines and GC could be the mechanism to ensure the normal
course of the inﬂammatory response, which requires the NF-jB
target gene expression, as well as some GR target genes.
4. Discussion
RAC3 is a coactivator of both GR and NF-jB [1,20,33], thus, the
fact that inﬂammatory cytokines and GC could be regulating its
expression levels is certainly no surprise.In this work, we found that mice stimulated with LPS, at a dose
that induces an inﬂammatory response was able to increase the
expression levels of RAC3 in the spleen. We observed that this hap-
pens at transcriptional level. Similar results were obtained in vitro
by stimulation with TNF, one of the inﬂammatory cytokines
induced by LPS and the principal mediator of septic shock [5].
Although LPS or another signal induced by LPS in physiological
conditions could be regulating the RAC3 levels, at least, TNF shows
to be an efﬁcient stimulus. Moreover, we found that this cytokine
increases the RAC3 promoter activity. Interestingly, although TNF
triggers several different intracellular signaling pathways, their
effect was blocked by addition of the NF-jB speciﬁc inhibitor SZ,
suggesting that this is the most important pathway to up regulate
the coactivator. Moreover, NF-jB activation could be one of the
signals by which the inﬂammatory response may increase the lev-
els of RAC3. In this regard, we found that RAC3 promoter has a
functional target sequence speciﬁc for NF-jB binding. In fact, this
promoter responds to TNF stimulation or Rel-A overexpression in
reporter assays and binding of the active transcription factor.
Taken together, all these results suggest that NF-jB activation
and binding to the RAC3 gene promoter leads to the up-regulation
of this coactivator during the inﬂammatory response.
In a physiological context, as part of the natural control of the
inﬂammatory response, the inﬂammatory cytokines activate the
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mRNA hRAC3 normalized to GAPDH and relativized to the control condition. (B)
HEK293 cells were transfected with the promRAC3-Luc plasmid; co-transfected at
similar experimental conditions as (A) and reporter activity was determined after
24 h. The diagram bars correspond to the average of relative light units (R.L.U.)
normalized with the corresponding b-Galactosidase values. (C) Protein levels were
determined by Western blot and diagram bars correspond to average ± SD of
relative densitometric units (R.D.U.) of three independent experiments, normalized
respect to the Tubulin expression. In all cases, results were analyzed by Tukey’s
Test.
C.V. Alvarado et al. / FEBS Open Bio 4 (2014) 450–457 455HPA axis inducing the increase of the anti-inﬂammatory GC in
order avoid the immune overreaction [4,32]. Thus, the increase of
RAC3 expression levels that was observed in vivo after 24 h of
LPS administration, are probably the result of a balance in the
crosstalk between the pro- and anti-inﬂammatory signals.In order to determine the speciﬁc effect of GC over the RAC3
expression, we analyzed the action of Dex administered both
in vivo and in vitro. In both cases, we found that the hormone
induces the increase of RAC3 expression. Moreover, our results of
qPCR and reporter assays suggest it could be happen at transcrip-
tional level, perhaps through a direct action of the activated GR and
binding to putative target sequences in the RAC3 gene promoter.
However, our results obtained in vivo and in vitro, where Dex
was administered together with LPS or TNF, suggest that additional
mechanisms related to the crosstalk with inﬂammatory signals
could not be excluded. In this regard, although each one of these
stimuli were RAC3 up-regulatory signals, no synergism was
observed in vivo or in vitro. Moreover, in vivo simultaneous stimu-
lation with LPS plus Dex shown to be mutually antagonistic, given
RAC3 mRNA levels similar to basal conditions. Meanwhile in vitro,
all the stimuli, alone or combined, induced the increase of RAC3
promoter and gene expression. The differences between the pro-
moter activity and gene expression could be explained perhaps,
because the reporter assays were performed only with a fragment
of the RAC3 promoter and additional regulatory sequences having
a role in the control of RAC3 gene expression are not included. Con-
cerning the antagonism, only observed in vivo, probably suggest
that GC-mediated inhibition of inﬂammatory cytokines synthesis
could be a limiting step for the increase of RAC3 expression. More-
over, in the physiological context, under LPS stimulation, the
hormone was unable to enhance the RAC3 gene expression. How-
ever, the cause of the observed differences between in vivo and
in vitro conditions and the precise molecular mechanism that are
involved, remains to be determined, although the GR and NF-jB
mutual antagonism appears to be the less probable [10,38].
It has been previously demonstrated that mice SRC-3/ are
more susceptible to infection in eye and skin [7,39] and markedly
hypersensitive to LPS-induced endotoxic shock [6]. In agreement
with previous reports, in response to LPS, SRC-3-/- macrophages
produce signiﬁcantly more pro-inﬂammatory cytokines such as
TNF, IL-6, and IL-1b than wild-type controls. Although they express
similar amounts of cytokine mRNAs, it was found that SRC-3 can
exert effects at translational levels, acting as a translational repres-
sor [41]. However, others have found that peritoneal macrophages
of SRC-3-deﬁcient mice showed a decrease in bacterial phagocyto-
sis in culture and an increase in apoptosis, which was consistent
with a defective bacterial clearance observed in SRC-3-deﬁcient
mice [6]. All together, these evidences strongly suggest an impor-
tant role for RAC3 in the control of the immune response. More-
over, all the previous reports support the knowledge that a
normal expression of this coactivator is required in order to ensure
the normal course of the immune response. In normal physiologi-
cal conditions, GC plays a central role avoiding the harmful effects
of the immune overreaction and is the best anti-inﬂammatory
control.
However, all this evidence arises from experiments performed
in knockout animals, where some compensatory mechanisms
could be developed during their life.
In agreement with our results concerning NF-jB and GR tran-
scriptional activity (Fig. 4) in a cell line having low levels of p160
coactivators [8], the absence of RAC3 shows to be a key limiting
factor for NF-jB and GR transactivation. This function could not
be compensated, at least within 24 h, by the activity of another
coactivator. Interestingly, the same low levels of coactivators could
be found in normal mouse and human tissues, while the constitu-
tive overexpression is related to tumoral cells.
Taken together, all our results suggest that, in normal condi-
tions, the increase of RAC3 during inﬂammatory response could
be a molecular mechanism that ensures the expression of NF-jB
and GR target genes required in the normal healthy course of the
immune and anti-inﬂammatory response.
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Fig. 4. RAC3 expression is required for NF-jB and GR-mediated transactivation: HEK293 cells transfected with RAC3 siRNA expression vector or the scrambled control and
co-transfected with the (A) jB-Luc or (B) GRE-Luc plasmid were stimulated with TNF (10 ng/ml), Dex (0.5 mM) or Dex plus TNF and reporter activity was determined after
24 h. The diagram bars correspond to the average of relative light units (R.L.U.) normalized with the corresponding b-Galactosidase values. (C) Diagram bars correspond to the
ampliﬁed scale of R.L.U. of jB-Luc and GRE-Luc activity in the presence of RAC3 siRNA. In all cases, results were analyzed by Tukey’s Test.
456 C.V. Alvarado et al. / FEBS Open Bio 4 (2014) 450–457Finally, RAC3 is an oncogene [27,40] that contributes to tumor
development when is overexpressed. An inﬂammatory response,
systemic or restricted to the tumor micro-environment plays an
important role in oncogenesis and some inﬂammatory cytokines
such as TNF, may contribute to tumorigenesis [28]. Therefore, the
possible RAC3 up-regulation by the inﬂammatory response in
tumors and surrounding tissues could be an important mechanism
that deserves special attention and research for a better under-
standing of this disease.
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